HC Wainwright Has Lowered Expectations for Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Price

Reviva Pharmaceuticals (NASDAQ:RVPH) had its price target lowered by HC Wainwright from $14.00 to $11.00 in a research note released on Wednesday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other analysts have also weighed in on the stock. Roth Capital raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 10th. Roth Mkm initiated coverage on Reviva Pharmaceuticals in a report on Friday, January 10th. They set a “buy” rating and a $7.00 price objective for the company. D. Boral Capital reiterated a “buy” rating and issued a $15.00 target price on shares of Reviva Pharmaceuticals in a research note on Tuesday. Finally, Maxim Group raised shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research note on Friday, January 10th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $11.40.

Reviva Pharmaceuticals Stock Down 3.0 %

RVPH stock opened at $1.94 on Wednesday. Reviva Pharmaceuticals has a twelve month low of $0.60 and a twelve month high of $4.83. The stock has a market capitalization of $64.88 million, a price-to-earnings ratio of -1.75 and a beta of -0.12. The firm’s fifty day simple moving average is $1.68 and its two-hundred day simple moving average is $1.33.

Hedge Funds Weigh In On Reviva Pharmaceuticals

An institutional investor recently bought a new position in Reviva Pharmaceuticals stock. Drive Wealth Management LLC acquired a new position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 20,000 shares of the company’s stock, valued at approximately $36,000. Drive Wealth Management LLC owned 0.06% of Reviva Pharmaceuticals at the end of the most recent reporting period. 63.18% of the stock is currently owned by hedge funds and other institutional investors.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.